Who can use MEXTOVI(Binimetinib)?

It is indicated for unresectable or metastatic melanoma and metastatic non-small cell lung cancer (NSCLC) with specific BRAF mutations.

Approved Uses

MEXTOVI, in combination with encorafenib, is approved for the treatment of adult patients with unresectable or metastatic melanoma harboring a BRAF V600E or V600K mutation, as detected by an FDA-approved test. It is also indicated for adult patients with metastatic NSCLC with a BRAF V600E mutation. confirmation of the mutation via an approved diagnostic test is mandatory prior to initiation of therapy.